Anti-CTLA4 toxicity associates with genetic variation correlating with serum antibody diversity
Year: 2018
Type: article
Study design: Observational Study
Abstract: Background: While anti-CTLA4 immunotherapy (IT) improves survival in metastatic melanoma patients, it manifests with severe toxicity. Recently, we identified serum antibody signatures associated with toxicity outcomes following anti-CTLA4 IT. In this study, capitalizing on our recent data showing that the expression of autoimmunity risk genes is controlled by germline genetic variation in melanoma survival, we tested whether antibody profiles linked with IT-related toxicity are impacted by underlying genetic variation.
Source: Annals of Oncology
Authors: D. Simpson, R. Ferguson, M. Gowen, K.M. Giles, J. Tchack, H. Zhou, U. Moran, Z. Dawood, A. Pavlick, S. Hu, M.A. Wilson, H. Zhong, M. Krogsgaard, J.S. Weber, I. Osman, T. Kirchhoff
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $5,080
OpenAlex ID: W2898091000